London, February 15, 2026, 11:26 GMT — The market has shut its doors.
GSK (GSK.L) heads into the week facing a dividend cutoff, the shares finishing Friday 1.1% higher at 2,161 pence. Sitting roughly 2.6% off its 52-week peak, the FTSE 100 name is set to trade ex-dividend on Feb. 19. (Hargreaves Lansdown)
Here’s why it’s crucial: “ex-dividend” marks the cutoff—purchase after that, you don’t collect the coming dividend. This detail attracts income-focused investors and can prompt a quick churn in holdings, regardless of any lack of new updates from the company.
GSK’s full-year results came with a Q4 dividend set at 18 pence a share. Looking ahead, the company is pointing to a 70 pence payout per share in 2026. The £2 billion share buyback? Still on track, running right through the end of Q2 2026. (GSK)
Stocks typically slip on the ex-dividend date—usually by about the size of the dividend itself—as fresh buyers lose their shot at that payout. The adjustment is automatic. Still, the way traders set up ahead of the move can leave the tape looking choppy.
But GSK’s yield isn’t the whole story for shareholders. New CEO Luke Miels isn’t just talking about dividends; he’s pushing to “accelerate what we have and to add to it via smart business development.” That means quicker drug launches and targeted acquisitions to bulk up the pipeline, not sprawling mega-deals. He’s also pegging revenue growth for 2026 at 3%-5% in constant currency, a figure that strips out currency swings. That same update drew attention to some rougher edges: uncertainty hangs over the U.S. vaccines segment, and upcoming HIV patent expiries could become a problem if pricing or demand slips. (Reuters)
GSK’s respiratory business has stayed in the spotlight, thanks to a string of recent product news. The company announced that the European Commission signed off on Nucala (mepolizumab) as an add-on maintenance therapy for certain COPD patients whose disease isn’t controlled by standard treatments. “Nucala could offer relief to the millions of Europeans who need additional options beyond inhaled triple therapy to manage their COPD,” said Kaivan Khavandi, who leads respiratory R&D. (GSK)
GSK said its regulatory application for Arexvy, the RSV vaccine aimed at adults 60 and up, has now been accepted by China’s Center for Drug Evaluation, putting a decision on the drug’s fate on the table for 2027. According to the company, the filing is supported by a Phase III trial in China that hit its main goals and confirmed the shot’s safety profile was within an acceptable range. (GSK)
Nothing major on the immediate horizon: ordinary shares lose their dividend rights on Feb. 19, with ADS holders following a day later, Feb. 20—the record date lands there, too. Payment hits on April 9. GSK’s own schedule has the next earnings release lined up for April 29, a date traders are watching once the dividend window closes. (GSK)
